Advances in cancer theranostics using organic-inorganic hybrid nanotechnology
Advances in cancer theranostics using organic-inorganic hybrid nanotechnology
复制标题
使用有机-无机混合纳米技术的癌症治疗诊断学进展
DOI：
10.1016/j.apmt.2021.101003
复制
发表时间：
2021-03-16
影响因子：
8.3
通讯作者：
Shen, Jianliang
中科院分区：
文献类型：
--
作者：
Chen, Gang;Qian, Yuna;Shen, Jianliang
药物溶解度差、稳定性差、生物相容性差、生物利用度差、药代动力学差、正常组织分布差、血液流变学受限、多药耐药（MDR）、转移等一系列障碍影响了肿瘤的治疗效果。纳米技术通过利用多种治疗方法/模式的不同作用机制，为解决这些问题提供了潜在的解决方案。在这方面，混合纳米材料具有巨大的应用潜力。在癌症诊断和治疗中，结合两种或两种以上纳米材料的独特物理和化学特性，可用于生产用于基因/药物传递、免疫治疗、分子诊断和生物成像的多功能新型纳米材料。这种混合材料的纳米平台通过协同杀伤靶肿瘤组织和细胞来扩展单组分系统的功能。本文将详细介绍目前在设计/开发、生物医学应用以及用于癌症治疗的最先进的有机-无机杂化纳米材料的治疗优势方面的进展。我们相信这类混合纳米技术可能为癌症的临床治疗和管理提供新的前景。(c) 2021 Elsevier Ltd.版权所有。
A series of barriers including poor drug solubility, stability, biocompatibility, bioavailability and pharmacokinetics, distribution to normal tissues, hemorheological flow limitations, multidrug resistance (MDR), and metastasis compromise cancer therapeutic effects. Nanotechnologies provide potential solutions to address these problems by taking advantage of distinct mechanisms of action of multiple therapeutics/modalities. In this regard, hybrid nanomaterials hold great promise for tremendous potential applications. In cancer diagnosis and therapy, a combination of the unique physical and chemical properties of two or more classes of nanomaterials can be used to produce versatile new categories of nanomaterials for gene/drug delivery, immunotherapy, molecular diagnostic, and bio-imaging. Such nanoplatforms of hybrid materials expand the functionality of single-component systems by synergistically killing of target tumor tissues and cells. This review will elaborate on current advances in the design/development, biomedical applications, and therapeutic advantages of state-of-the-art organic-inorganic hybrid nanomaterials used in cancer theranostics. We believe that this class of hybrid nanotechnology might provide new prospects for clinical therapy and management of cancer.(c) 2021 Elsevier Ltd. All rights reserved.